Clariness today announced it has acquired Viomedo, a leading online platform for clinical trials and provider of patient enrollment services

Over the last 13 years, Clariness has built a patient recruitment business covering 45 countries and 8 of
the top 10 pharmaceutical companies. “Clinical trials face increasing challenges in terms of cost and
timelines. Clariness strives to drive innovation in clinical development for the pharmaceutical industry,”
Michael Stadler, CEO and Co-Founder of Clariness, said. “Viomedo’s best-in-class approach to involve
patients, reduce their barriers to find and participate in trials and innovative technology will be an
excellent complement to our established patient recruitment and retention portfolio. Viomedo will enable
Clariness to provide our clients with even deeper ties to local patient communities, exclusive recruitment
channels and higher randomization rates that support their strategies and delivery.”

Viomedo has established the largest search engine for clinical trials in Germany. Their platform has been
awarded by among others the Federal Ministry for Economic Affairs and Energy (BMWi). Their services
support leading research institutions, life sciences companies and CROs with their clinical research
through their online platform and network of partners, such as patient advocacy groups.

“We are very excited about the opportunity to join forces with Clariness”, Alexander Puschilov, Co-
Founder and CEO of Viomedo said. “Having the chance to leverage Viomedo’s unique technology and
local strength across Clariness broad geographic and service portfolio, will enable us to offer clients
unique solutions for data-driven trial planning, site selection, patient recruitment and retention. In
addition, we can’t wait what else will result from our joined expertise.”